Clinical Laboratory Services/standards; Hepcidins/blood; Humans; Immunochemistry; International Cooperation; Linear Models; Reference Standards
Abstract :
[en] BACKGROUND: Absolute plasma hepcidin concentrations measured by various procedures differ substantially, complicating interpretation of results and rendering reference intervals method dependent. We investigated the degree of equivalence achievable by harmonization and the identification of a commutable secondary reference material to accomplish this goal. METHODS: We applied technical procedures to achieve harmonization developed by the Consortium for Harmonization of Clinical Laboratory Results. Eleven plasma hepcidin measurement procedures (5 mass spectrometry based and 6 immunochemical based) quantified native individual plasma samples (n = 32) and native plasma pools (n = 8) to assess analytical performance and current and achievable equivalence. In addition, 8 types of candidate reference materials (3 concentrations each, n = 24) were assessed for their suitability, most notably in terms of commutability, to serve as secondary reference material. RESULTS: Absolute hepcidin values and reproducibility (intrameasurement procedure CVs 2.9%-8.7%) differed substantially between measurement procedures, but all were linear and correlated well. The current equivalence (intermeasurement procedure CV 28.6%) between the methods was mainly attributable to differences in calibration and could thus be improved by harmonization with a common calibrator. Linear regression analysis and standardized residuals showed that a candidate reference material consisting of native lyophilized plasma with cryolyoprotectant was commutable for all measurement procedures. Mathematically simulated harmonization with this calibrator resulted in a maximum achievable equivalence of 7.7%. CONCLUSIONS: The secondary reference material identified in this study has the potential to substantially improve equivalence between hepcidin measurement procedures and contributes to the establishment of a traceability chain that will ultimately allow standardization of hepcidin measurement results.
Research center :
CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
van der Vorm, Lisa N.
Hendriks, Jan C. M.
Laarakkers, Coby M.
Klaver, Siem
Armitage, Andrew E.
Bamberg, Alison
Geurts-Moespot, Anneke J.
Girelli, Domenico
Herkert, Matthias
Itkonen, Outi
Konrad, Robert J.
Tomosugi, Naohisa
Westerman, Mark
Bansal, Sukhvinder S.
Campostrini, Natascia
Drakesmith, Hal
Fillet, Marianne ; Université de Liège > Département de pharmacie > Analyse des médicaments
Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117: 4425-33.
Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: Diagnostic implications. Clin Chem 2011;57: 1650-69.
Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306: 2090-3.
De Falco L, Silvestri L, Kannengiesser C, Moran E, Oudin C, Rausa M, et al. Functional and clinical impact of novel TMPRSS6 variants in iron-refractory iron-deficiency anemia patients and genotype-phenotype studies. Hum Mutat 2014;35: 1321-9.
Donker AE, Raymakers RA, Vlasveld LT, van Barneveld T, Terink R, Dors N, et al. Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis. Blood 2014;123: 3873-86.
Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al. Regulation of iron homeostasis inanemiaof chronic disease and iron deficiency anemia: Diagnostic and therapeutic implications. Blood 2009;113: 5277-86.
van Santen S, van Dongen-Lases EC, de Vegt F, Laarakkers CM, van Riel PL, van Ede AE, Swinkels DW. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum 2011;63: 3672-80.
Ganz T. Hepcidin and the global burden of iron deficiency. Clin Chem 2015;61: 577-8.
Camaschella C. Treating iron overload. N Engl J Med 2013;368: 2325-7.
Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci 2014;35: 155-61.
Kroot JJ, van Herwaarden AE, Tjalsma H, Jansen RT, Hendriks JC, Swinkels DW. Second round robin for plasma hepcidin methods: First steps toward harmonization. Am J Hematol 2012;87: 977-83.
Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: Need for standardization. Haematologica 2009;94: 1748-52.
ISO. In vitro diagnostic medical devices-measurement of quantities in biological samples-metrological traceability of values assigned to calibrators and control materials- first edition. Geneva: ISO; 2003. ISO 17511: 2003.
Clark RJ, Tan CC, Preza GC, Nemeth E, Ganz T, Craik DJ. Understanding the structure/activity relationships of the iron regulatory peptide hepcidin. Chem Biol 2011; 18: 336-43.
Jordan JB, Poppe L, Haniu M, Arvedson T, Syed R, Li V, et al. Hepcidin revisited, disulfide connectivity, dynamics, and structure. J Biol Chem 2009;284: 24155-67.
Miller WG, Myers GL, Gantzer ML, Kahn SE, Schönbrunner ER, Thienpont LM, et al. Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 2013;59: 1291-3.
Weykamp C, Eckfeldt J, Roberts W, Vesper H, Thienpont L, Burns C, et al. International Consortium for Harmonization of Clinical Laboratory Results. Toolbox of technical procedures to be considered when developing a process to achieve harmonization for a measurand. www.harmonization.net (Accessed December 2015).
Laarakkers CM, Wiegerinck ET, Klaver S, Kolodziejczyk M, Gille H, Hohlbaum AM, et al. Improved mass spectrometry assay for plasma hepcidin: Detection and characterization of a novel hepcidin isoform. PLoS One 2013;8: E75518.
CLSI. Characterization and qualification of commutable reference materials for laboratory medicine: Approved guideline. Wayne, PA: CLSI; 2010. CLSI document EP30-A (formerly C53-A).
Fraser CG, Hyltoft Peterson P, Libeer JC, Ricos C. Proposal for setting generally applicable quality goals solely based on biology. Ann Clin Biochem 1997;34: 8-12.
Murphy AT, Witcher DR, Luan P, Wroblewski VJ. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood 2007;110: 1048-54.
Itkonen O, Parkkinen J, Stenman UH, Hämäläinen E. Preanalytical factors and reference intervals for serum hepcidin LC-MS/MS method. Clin Chim Acta 2012; 413: 696-701.
Huang ML, Austin CJ, Sari MA, Rahmanto YS, Ponka P, Vyoral D, Richardson DR. Hepcidin bound to 2- macroglobulin reduces ferroportin-1 expression and enhances its activity at reducing serum iron levels. J Biol Chem 2013;288: 25450-65.
Itkonen O, Stenman UH, Parkkinen J, Soliymani R, Baumann M, Hämäläinen E. Binding of hepcidin to plasma proteins. Clin Chem 2012;58: 1159-60.
Peslova G, Petrak J, Kuzelova K, Hrdy I, Halada P, Kuchel PW, et al. Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood 2009;113: 6225-36.
Ruijter GJ, Boer M, Weykamp CW, de Vries R, van den Berg I, Janssens-Puister J, et al. External quality assurance programme for enzymatic analysis of lysosomal storage diseases: A pilot study. J Inherit Metab Dis 2005;28: 979-90.
Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 2007;21: 4033-8.
Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, Poli A, et al. Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol 2010; 2010: 329646.
Wolff F, Deleers M, Melot C, Gulbis B, Cotton F. Hepcidin-25: Measurement by LC-MS/MS in serum and urine, reference ranges and urinary fractional excretion. Clin Chim Acta 2013;23: 99-104.
Kroot JJC, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 2010;56: 1570-9.
Butterfield AM, Luan P, Witcher DR, Manetta J, Murphy AT, Wroblewski VJ, Konrad RJ. A dual-monoclonal sandwich ELISA specific for hepcidin-25. Clin Chem 2010;56: 1725-32.
Pasricha SR, Atkinson SH, Armitage AE, Khandwala S, Veenemans J, Cox SE, et al. Expression of the iron hormone hepcidin distinguishes different types of anemia in African children. Sci Transl Med 2014;6: 235re3.
Prentice AM, Doherty CP, Abrams SA, Cox SE, Atkinson SH, Verhoef H, et al. Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood 2012;119: 1922- 8.
Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 2008; 112: 4292-7.
Zipperer E, Post JG, Herkert M, Kü ndgen A, Fox F, Haas R, et al. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome. Ann Hematol 2013;92: 1617-23.